Skip to main content
. 2017 Apr 3;36(32):4641–4652. doi: 10.1038/onc.2017.91

Figure 5.

Figure 5

Noncanonical activation of GLI1 in LAC cells. (a, b) Western blots of endogenous protein levels of NRP2, GLI1 and P-ERK1/2 and actin (LC) in commercial LAC cell lines (H1734, H1437) and CSCs 2, 3, 4 after siRNA-mediated (a) or short-hairpin-mediated (b) silencing of NRP2. Bar graphs: densitometric analyses. Dashed line: CTRL treatment. (cf) Cell viability (MTS assay) in (c) LAC cell lines after siRNA silencing of NRP2, GLI1 and both; in (d) CSCs after short-hairpin mediated silencing of NRP2, GLI1 and both; and in (e) in LAC cell lines and (f) LAC CSCs treated for 48 h with GANT61, U0126 or both. *P<0.05, **P<0.01 vs sham-treated/sham-transfected controls.